Social conditions, such as income, employment and family resources, matter for health, and health matters for participation in society, employment and economic well-being. These associations are well known.
In CP-North a highly qualified multidisciplinary team of researchers from all major Nordic countries will address a number of societal challenges associated with living with, or being a parent of a child, with a life-long disability in Norden by merging data from national registers with unique health data from quality registers.
The workplace, along with the school, primary care and hospital, has been established as one of the priority settings for health promotion. Work-related factors may influence the health of employees in various ways and, in the long run, contribute to healthy ageing.
Linking the detailed information of the spatio-temporal distribution of air pollution levels and the chemical composition of the atmospheric particles with register data for mortality and morbidity, we have a unique opportunity in the Nordic countries to gain new understanding of the various health impacts from different kinds of air pollution from different kind of sources.
During the last decades refugee immigration has changed the societal weave of the Nordic welfare states. There are many indications that the socioeconomic as well as the health situation of these new Nordic citizens are less favourable compared with the majority populations.
Acute myelogenous leukemia (AML) is the most coomon acute leukemia in adults with and annual incidence of 4 cases per 100 000 inhabitans. Median age at diagnosis is 70 years. For patients below 55 years, the prognosis has gradually improved the last decades, but elderly patiens still do poorly; the survival being around 30% with no improvement of outome after standard chemotherapy treatment.
The NORD-STAR clinical trial will provide extremely valuable information on the treatment of early rheumatoid arthritis. The study aims to find out, which is the most effective treatment strategy in early rheumatoid arthritis. As the first trial ever it will compare four different treatment modalities head-to-head.
Crohn's disease is a chronic inflammatory bowel disease. The biological drug Remicade is used in patients with Crohn's disease when normal treatment is inadequate. About one in three of the patients starting treatment with Remicade have sustained good effect over several years. However, serious side effects such as; infections, allergic reactions and concerns about long-term safety, with suspected increased risk of developing cancer, necessitate exploring strategies for when and in which patients to stop (discontinue) treatment again.
Ved at øge tilgængeligheden til sundhedsdata har Norden potentialet til at blive verdensførende inden for forskning, sundhedspleje og innovation. En netop udkommet rapport fra NordForsk skitserer en handlingsplan for implementering af en nordisk digital infrastruktur for sundhedsdata – Nordic Commons. Rapporten er resultatet af en to-årig indsats med det formål at øge det nordiske samarbejde om sundhedsdata.
